A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors

Last updated: March 21, 2022
Sponsor: Betta Pharmaceuticals Co., Ltd.
Overall Status: Active - Recruiting

Phase

1

Condition

Neoplasm Metastasis

Treatment

N/A

Clinical Study ID

NCT05302843
BTP-661211
  • Ages > 18
  • All Genders

Study Summary

This is an open-labe Phase I study of BPI-28592 for the treatment of patients with solid tumors

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histologically- or cytologically-confirmed diagnosis of locally advanced or metastaticsolid tumor
  • At least 18 years of age
  • Measurable or evaluable disease
  • Adequate organ function as defined per protocol

Exclusion

Exclusion Criteria:

  • Symptomatic or unstable brain metastases
  • Pregnancy or lactation
  • Other protocol specified criteria

Study Design

Total Participants: 40
Study Start date:
March 22, 2021
Estimated Completion Date:
December 31, 2023

Connect with a study center

  • Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine

    HangZhou, Zhejiang
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.